Quick Answer
ACTUATE THERAPEUTICS, INC. reported Net Income of -$22.23 million for fiscal year 2025.
ACTUATE THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$22.23M +18.5% |
-$27.29M -10.3% |
-$24.74M | — |
| Diluted EPS | -$1.06 +67.5% |
-$3.26 +81.1% |
-$17.24 | — |
| Total Assets | $14.04M +50.6% |
$9.32M +211.1% |
$3.00M | — |
| Stockholders Equity | $7.92M +7505.6% |
$104.2K +100.1% |
-$99.63M -32.3% |
-$75.31M |
| R&D Expense | $10.29M -44.9% |
$18.68M -14.0% |
$21.71M | — |
| Operating Income | -$22.50M +10.6% |
-$25.16M -0.7% |
-$24.97M | — |
| Shares Outstanding | 23.25M +19.0% |
19.53M +1055.2% |
1.69M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$5.41M | +9.4% | +9.1% |
| Diluted EPS | September 30, 2025 | -$0.25 | +54.5% | +16.7% |
| Total Assets | September 30, 2025 | $17.71M | +24.2% | +154.2% |
| Stockholders Equity | September 30, 2025 | $10.94M | +104.1% | +512.1% |
| R&D Expense | September 30, 2025 | $2.18M | -42.0% | -21.2% |
| Operating Income | September 30, 2025 | -$5.47M | -1.5% | +8.3% |
| Shares Outstanding | September 30, 2025 | 23.24M | +19.0% | +13.5% |
- ACTUATE THERAPEUTICS, INC. reported Net Income of -$22.23 million for fiscal year 2025.
- ACTUATE THERAPEUTICS, INC. showed an increase of +18.5% in Net Income compared to the prior fiscal year.
- ACTUATE THERAPEUTICS, INC. reported Diluted EPS of $1.06 per share (loss) for fiscal year 2025.
- ACTUATE THERAPEUTICS, INC. showed an increase of +67.5% in Diluted EPS compared to the prior fiscal year.
- ACTUATE THERAPEUTICS, INC. reported Total Assets of $14.04 million for fiscal year 2025.
- ACTUATE THERAPEUTICS, INC. showed an increase of +50.6% in Total Assets compared to the prior fiscal year.
- ACTUATE THERAPEUTICS, INC. reported Stockholders Equity of $7.92 million for fiscal year 2025.
- ACTUATE THERAPEUTICS, INC. showed an increase of +7505.6% in Stockholders Equity compared to the prior fiscal year.
- ACTUATE THERAPEUTICS, INC. reported R&D Expense of $10.29 million for fiscal year 2025.
- ACTUATE THERAPEUTICS, INC. showed a decrease of -44.9% in R&D Expense compared to the prior fiscal year.
- ACTUATE THERAPEUTICS, INC. reported Operating Income of -$22.50 million for fiscal year 2025.
- ACTUATE THERAPEUTICS, INC. showed an increase of +10.6% in Operating Income compared to the prior fiscal year.
- ACTUATE THERAPEUTICS, INC. reported Shares Outstanding of 23.25 million shares for fiscal year 2025.
- ACTUATE THERAPEUTICS, INC. showed an increase of +19.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: